Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Show more

Location: 100 Marine Parkway, Redwood City, CA, 94065, United States | Website: https://soleno.life | Industry: Biotechnology | Sector: Healthcare

Market Cap

4.60B

52 Wk Range

$41.50 - $90.32

Previous Close

$87.64

Open

$88.25

Volume

1,187,600

Day Range

$86.24 - $88.82

Enterprise Value

3.985B

Cash

290M

Avg Qtr Burn

-22.33M

Insider Ownership

1.89%

Institutional Own.

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VYKAT XR (diazoxide choline) (DCCR) Details Prader-Willi syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.